134 related articles for article (PubMed ID: 26383153)
1. Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors.
Sharma R; Kallur KG; Ryu JS; Parameswaran RV; Lindman H; Avril N; Gleeson FV; Lee JD; Lee KH; O'Doherty MJ; Groves AM; Miller MP; Somer EJ; Coombes CR; Aboagye EO
J Nucl Med; 2015 Dec; 56(12):1855-61. PubMed ID: 26383153
[TBL] [Abstract][Full Text] [Related]
2. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.
Battle MR; Goggi JL; Allen L; Barnett J; Morrison MS
J Nucl Med; 2011 Mar; 52(3):424-30. PubMed ID: 21321268
[TBL] [Abstract][Full Text] [Related]
3. [¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins.
Mena E; Owenius R; Turkbey B; Sherry R; Bratslavsky G; Macholl S; Miller MP; Somer EJ; Lindenberg L; Adler S; Shih J; Choyke P; Kurdziel K
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1879-88. PubMed ID: 24973039
[TBL] [Abstract][Full Text] [Related]
4. In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis.
Jenkins WS; Vesey AT; Vickers A; Neale A; Moles C; Connell M; Joshi NV; Lucatelli C; Fletcher AM; Spratt JC; Mirsadraee S; van Beek EJ; Rudd JH; Newby DE; Dweck MR
Heart; 2019 Dec; 105(24):1868-1875. PubMed ID: 31422361
[TBL] [Abstract][Full Text] [Related]
5. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
6. Test-Retest Variability in Lesion SUV and Lesion SUR in
Hofheinz F; Apostolova I; Oehme L; Kotzerke J; van den Hoff J
J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598
[TBL] [Abstract][Full Text] [Related]
7. [
Sharma R; Valls PO; Inglese M; Dubash S; Chen M; Gabra H; Montes A; Challapalli A; Arshad M; Tharakan G; Chambers E; Cole T; Lozano-Kuehne JP; Barwick TD; Aboagye EO
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1239-1251. PubMed ID: 31754793
[TBL] [Abstract][Full Text] [Related]
8. Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
Weber WA; Gatsonis CA; Mozley PD; Hanna LG; Shields AF; Aberle DR; Govindan R; Torigian DA; Karp JS; Yu JQ; Subramaniam RM; Halvorsen RA; Siegel BA; ;
J Nucl Med; 2015 Aug; 56(8):1137-43. PubMed ID: 25908829
[TBL] [Abstract][Full Text] [Related]
9. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
10. Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PET.
Kenny LM; Tomasi G; Turkheimer F; Larkin J; Gore M; Brock CS; Mangar S; Aboagye EO
EJNMMI Res; 2014 Dec; 4(1):30. PubMed ID: 26055935
[TBL] [Abstract][Full Text] [Related]
11. Test-Retest Reproducibility of
Kurland BF; Peterson LM; Shields AT; Lee JH; Byrd DW; Novakova-Jiresova A; Muzi M; Specht JM; Mankoff DA; Linden HM; Kinahan PE
J Nucl Med; 2019 May; 60(5):608-614. PubMed ID: 30361381
[TBL] [Abstract][Full Text] [Related]
12. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility and Repeatability of Semiquantitative
Vargas HA; Kramer GM; Scott AM; Weickhardt A; Meier AA; Parada N; Beattie BJ; Humm JL; Staton KD; Zanzonico PB; Lyashchenko SK; Lewis JS; Yaqub M; Sosa RE; van den Eertwegh AJ; Davis ID; Ackermann U; Pathmaraj K; Schuit RC; Windhorst AD; Chua S; Weber WA; Larson SM; Scher HI; Lammertsma AA; Hoekstra OS; Morris MJ
J Nucl Med; 2018 Oct; 59(10):1516-1523. PubMed ID: 29626121
[No Abstract] [Full Text] [Related]
15. Measurement Repeatability of
Fraum TJ; Fowler KJ; Crandall JP; Laforest RA; Salter A; An H; Jacobs MA; Grigsby PW; Dehdashti F; Wahl RL
J Nucl Med; 2019 Aug; 60(8):1080-1086. PubMed ID: 30733325
[TBL] [Abstract][Full Text] [Related]
16. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
17. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
18. Cardiac α
Jenkins WS; Vesey AT; Stirrat C; Connell M; Lucatelli C; Neale A; Moles C; Vickers A; Fletcher A; Pawade T; Wilson I; Rudd JH; van Beek EJ; Mirsadraee S; Dweck MR; Newby DE
Heart; 2017 Apr; 103(8):607-615. PubMed ID: 27927700
[TBL] [Abstract][Full Text] [Related]
19. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
[TBL] [Abstract][Full Text] [Related]
20. PET of αvbeta3-integrin and αvbeta5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time?
Beer AJ; Schwaiger M
J Nucl Med; 2011 Mar; 52(3):335-7. PubMed ID: 21321266
[No Abstract] [Full Text] [Related]
[Next] [New Search]
